223 related articles for article (PubMed ID: 31351062)
1. Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses.
Gentry-Maharaj A; Burnell M; Dilley J; Ryan A; Karpinskyj C; Gunu R; Mallett S; Deeks J; Campbell S; Jacobs I; Sundar S; Menon U
Am J Obstet Gynecol; 2020 Jan; 222(1):56.e1-56.e17. PubMed ID: 31351062
[TBL] [Abstract][Full Text] [Related]
2. Ultrasound Features Improve Diagnostic Performance of Ovarian Cancer Predictors in Distinguishing Benign and Malignant Ovarian Tumors.
Chen YN; Ma F; Zhang YD; Chen L; Li CY; Gong SP
Curr Med Sci; 2020 Feb; 40(1):184-191. PubMed ID: 32166682
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
[TBL] [Abstract][Full Text] [Related]
4. Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial.
Menon U; Gentry-Maharaj A; Burnell M; Ryan A; Kalsi JK; Singh N; Dawnay A; Fallowfield L; McGuire AJ; Campbell S; Skates SJ; Parmar M; Jacobs IJ
Health Technol Assess; 2023 May; ():1-81. PubMed ID: 37183782
[TBL] [Abstract][Full Text] [Related]
5. HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients.
Braicu EI; Krause CL; Torsten U; Mecke H; Richter R; Hellmeyer L; Lanowska M; Müller B; Koch E; Boenneß-Zaloum J; Ames K; Chekerov R; Hasenbein K; Zimmermann M; Mangler M; Chen F; Tauber R; Sehouli J
BMC Cancer; 2022 Jul; 22(1):831. PubMed ID: 35907794
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Menon U; Gentry-Maharaj A; Hallett R; Ryan A; Burnell M; Sharma A; Lewis S; Davies S; Philpott S; Lopes A; Godfrey K; Oram D; Herod J; Williamson K; Seif MW; Scott I; Mould T; Woolas R; Murdoch J; Dobbs S; Amso NN; Leeson S; Cruickshank D; McGuire A; Campbell S; Fallowfield L; Singh N; Dawnay A; Skates SJ; Parmar M; Jacobs I
Lancet Oncol; 2009 Apr; 10(4):327-40. PubMed ID: 19282241
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Performance of F-18 FDG PET/CT Compared with CA125, HE4, and ROMA for Epithelial Ovarian Cancer.
Lee SS; Park JS; Lee KB; Jeong DH; Byun JM; Lee SM
Asian Pac J Cancer Prev; 2021 Apr; 22(4):1123-1127. PubMed ID: 33906304
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the predictive performance of risk of malignancy indexes 1-4, HE4 and risk of malignancy algorithm in the triage of adnexal masses.
Hada A; Han LP; Chen Y; Hu QH; Yuan Y; Liu L
J Ovarian Res; 2020 Apr; 13(1):46. PubMed ID: 32334618
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
Ahmed AA; Abdou AM
Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass].
Shipeng G; Yongning C; Yadi Z; Chanyuan LI; Qifan J
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Dec; 39(12):1393-1401. PubMed ID: 31907150
[TBL] [Abstract][Full Text] [Related]
11. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.
Zhang L; Chen Y; Wang K
Curr Probl Cancer; 2019 Apr; 43(2):135-144. PubMed ID: 30017407
[TBL] [Abstract][Full Text] [Related]
12. The diagnostic accuracy of human epididymis protein 4 (HE4) for discriminating between benign and malignant pelvic masses: a systematic review and meta-analysis.
Olsen M; Lof P; Stiekema A; van den Broek D; Wilthagen EA; Bossuyt PM; Lok CAR
Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1788-1799. PubMed ID: 34212386
[TBL] [Abstract][Full Text] [Related]
13. Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS).
Sharma A; Apostolidou S; Burnell M; Campbell S; Habib M; Gentry-Maharaj A; Amso N; Seif MW; Fletcher G; Singh N; Benjamin E; Brunell C; Turner G; Rangar R; Godfrey K; Oram D; Herod J; Williamson K; Jenkins H; Mould T; Woolas R; Murdoch J; Dobbs S; Leeson S; Cruickshank D; Fourkala EO; Ryan A; Parmar M; Jacobs I; Menon U
Ultrasound Obstet Gynecol; 2012 Sep; 40(3):338-44. PubMed ID: 22911637
[TBL] [Abstract][Full Text] [Related]
14. HE4 might be a more useful tumor biomarker to detect malignancy in patients with ovarian endometrioma when malignancy is suspected.
Rius M; Fusté P; Ros C; Martínez-Zamora Á; deGuirior C; Gracia M; Mension E; Carmona F
J Int Med Res; 2021 Sep; 49(9):3000605211047701. PubMed ID: 34590878
[TBL] [Abstract][Full Text] [Related]
15. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
16. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
17. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.
Li F; Tie R; Chang K; Wang F; Deng S; Lu W; Yu L; Chen M
BMC Cancer; 2012 Jun; 12():258. PubMed ID: 22712526
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
19. CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.
Wang Z; Tao X; Ying C
Dis Markers; 2019; 2019():6241743. PubMed ID: 31737130
[TBL] [Abstract][Full Text] [Related]
20. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.
Li W; Wang D
Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
